These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12622756)

  • 1. Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion.
    Lindberg P; Keeling D; Fryklund J; Andersson T; Lundborg P; Carlsson E
    Aliment Pharmacol Ther; 2003 Feb; 17(4):481-8. PubMed ID: 12622756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
    Andersson T; Röhss K; Bredberg E; Hassan-Alin M
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1563-9. PubMed ID: 11563995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: esomeprazole--the first proton pump inhibitor to be developed as an isomer.
    Kendall MJ
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():1-4. PubMed ID: 12614298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor.
    Tonini M; Vigneri S; Savarino V; Scarpignato C
    Dig Liver Dis; 2001 Oct; 33(7):600-6. PubMed ID: 11816552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.
    Hatlebakk JG
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():10-5; discussion 16-7. PubMed ID: 12614300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: pharmacology of esomeprazole and comparisons with omeprazole.
    Dent J
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():5-9. PubMed ID: 12614299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
    Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Mullner K; Molnar B; Tulassay Z
    Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The choice of proton pump inhibitor: does it matter?
    Hellström PM; Vitols S
    Basic Clin Pharmacol Toxicol; 2004 Mar; 94(3):106-11. PubMed ID: 15049339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving opportunities for effective management of gastro-oesophageal reflux disease.
    Vigneri S; Tonini M; Scarpignato C; Savarino V
    Dig Liver Dis; 2001 Nov; 33(8):720-30. PubMed ID: 11785720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM; Vitols S
    Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.